Stocks · News reference
Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference
Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Darden, ServiceNow, Robinhood, Ibex and Workiva, while cutting targets for McDonald’s, Cerenome and Wingstop.
Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
8-K filing — CERENOME, INC. (CNSY)
Filed: 2026-09-10 AccNo: 0001193125-26-387267 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits